mrpl-45 Antibody

What criteria should be considered when selecting an MRPL45 antibody for research?

When selecting an MRPL45 antibody, researchers should evaluate multiple parameters to ensure experimental success. The first consideration should be antibody specificity - confirming the antibody recognizes the target epitope with minimal cross-reactivity. This is particularly important for MRPL45, as mitochondrial proteins may share structural similarities with other cellular components. Consider the host species (rabbit and mouse options are commercially available) and format (monoclonal versus polyclonal) .

Application compatibility is crucial - different experimental techniques require antibodies validated for specific applications. For MRPL45, available antibodies demonstrate varying performance across Western blot, immunohistochemistry, immunofluorescence, immunoprecipitation, and ELISA applications . Species reactivity must align with your experimental model, with most commercial MRPL45 antibodies showing reactivity toward human, mouse, and rat samples .

The immunogen used to generate the antibody provides insight into which domain or region of MRPL45 is being targeted. For example, CAB13197 was generated using a recombinant fusion protein containing amino acids 57-306 of human MRPL45 , while other antibodies may target different regions, potentially affecting recognition of specific isoforms or post-translationally modified variants.

How can I validate the specificity of an MRPL45 antibody for my research application?

Validating antibody specificity is essential for generating reliable experimental data. For MRPL45 antibodies, employ a multi-step validation strategy beginning with positive and negative controls. Positive controls should include cell lines or tissues known to express MRPL45, such as HeLa, HEK-293, or Jurkat cells for human samples, or mouse liver tissue for murine studies .

Western blot validation should confirm a single band at the expected molecular weight of approximately 33-35 kDa . The presence of multiple bands may indicate cross-reactivity or protein degradation. For further validation, consider genetic approaches such as siRNA/shRNA knockdown or CRISPR-Cas9 knockout of MRPL45, which should result in reduced or absent signal.

Immunofluorescence validation should demonstrate co-localization with established mitochondrial markers, as MRPL45 is specifically localized to mitochondria. Additionally, recombinant protein blocking experiments can confirm specificity - pre-incubating the antibody with purified MRPL45 protein should abolish the signal in your application of interest.

Document positive detection in validated sample types. For example, 15682-1-AP has been positively validated in HeLa cells, mouse liver tissue, and SKOV-3 cells for Western blot applications .

What are the optimal conditions for Western blot analysis using MRPL45 antibodies?

Optimal Western blot conditions for MRPL45 detection require careful consideration of sample preparation, antibody dilution, and detection protocols. Begin with proper sample preparation by isolating proteins using a buffer containing protease inhibitors to prevent degradation of the target protein. For mitochondrial proteins like MRPL45, consider mitochondrial enrichment protocols to increase detection sensitivity.

The recommended antibody dilutions vary by manufacturer and specific antibody clone:

For protein separation, use 10-12% SDS-PAGE gels, which provide optimal resolution for proteins in the 33-35 kDa range . Transfer conditions may require optimization, with semi-dry transfer at 15-20V for 30-45 minutes often yielding good results for proteins of this size.

For blocking, 5% non-fat dry milk in TBST (Tris-buffered saline with 0.1% Tween-20) is typically effective, though 5% BSA may provide lower background in some cases. Incubate with primary antibody in blocking buffer overnight at 4°C for optimal binding. Secondary antibody selection should match the host species of your primary antibody (anti-rabbit for 15682-1-AP or anti-mouse for 66531-1-Ig) and be used at dilutions of 1:5000-1:10000 .

How should immunohistochemistry (IHC) protocols be optimized for MRPL45 detection in tissue samples?

Successful immunohistochemical detection of MRPL45 requires careful attention to fixation, antigen retrieval, and staining conditions. Formalin-fixed, paraffin-embedded (FFPE) tissues are commonly used, with 10% neutral buffered formalin recommended for fixation.

Antigen retrieval is critical for MRPL45 detection, with both high and low pH buffers showing utility depending on the specific antibody. For 15682-1-AP, TE buffer at pH 9.0 is suggested as the primary option, with citrate buffer at pH 6.0 as an alternative . Similar recommendations apply for 66531-1-Ig . Optimize retrieval time (typically 10-20 minutes) in a pressure cooker or microwave.

Appropriate dilutions for IHC applications vary by antibody:

To minimize background staining, include a peroxidase blocking step (3% hydrogen peroxide for 10 minutes) and use a protein block (5% normal serum from the same species as the secondary antibody). For visualization, both DAB (3,3'-diaminobenzidine) and AEC (3-amino-9-ethylcarbazole) chromogens are suitable, with DAB providing a brown precipitate and AEC a red precipitate .

What are the best practices for immunofluorescence applications with MRPL45 antibodies?

Immunofluorescence detection of MRPL45 requires specific considerations due to its mitochondrial localization. Cell fixation should be performed with 4% paraformaldehyde for 15-20 minutes at room temperature, as this preserves mitochondrial morphology better than methanol fixation. For permeabilization, 0.1-0.2% Triton X-100 for 5-10 minutes is generally effective.

The recommended antibody dilutions for immunofluorescence vary:

For co-localization studies, consider combining MRPL45 antibody staining with established mitochondrial markers such as TOMM20, COX IV, or MitoTracker dyes. When using NBP2-97306JF549, which is directly conjugated with Janelia Fluor 549, a red fluorescent dye, co-staining with green fluorescent markers (e.g., FITC-conjugated antibodies) is recommended for optimal spectral separation .

To minimize background, include a blocking step with 5-10% normal serum from the same species as the secondary antibody, and add 0.1-0.3% Tween-20 to all antibody diluents. For mitochondrial proteins, confocal microscopy is preferred over epifluorescence to better resolve the intricate mitochondrial network structure .

How can MRPL45 antibodies be utilized in co-immunoprecipitation studies to investigate protein-protein interactions?

Co-immunoprecipitation (Co-IP) with MRPL45 antibodies can reveal critical interactions within the mitochondrial ribosome complex and identify novel binding partners. For successful Co-IP experiments, several technical considerations should be addressed.

Begin with gentle cell lysis to preserve protein-protein interactions. A buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% NP-40 or 0.5% Triton X-100, with protease inhibitors and phosphatase inhibitors is generally suitable. For mitochondrial protein interactions, consider using a mitochondrial isolation protocol prior to lysis to enrich for the target organelle.

For immunoprecipitation, the 15682-1-AP antibody has been validated and is recommended at 0.5-4.0 μg per 1.0-3.0 mg of total protein lysate . Pre-clearing the lysate with Protein A/G beads can reduce non-specific binding. Incubate the cleared lysate with MRPL45 antibody overnight at 4°C with gentle rotation, followed by addition of Protein A (for rabbit antibodies) or Protein G (for mouse antibodies) beads for 1-2 hours.

After thorough washing with lysis buffer, elute the immunoprecipitated proteins and analyze by Western blot, probing for both MRPL45 (as control) and suspected interaction partners. Consider using a non-related IgG as a negative control to confirm the specificity of detected interactions.

For challenging interactions or transient associations, crosslinking with DSP (dithiobis[succinimidyl propionate]) or formaldehyde before lysis can stabilize protein complexes. Alternatively, proximity labeling methods like BioID or APEX2 fused to MRPL45 can provide a complementary approach to identify the proximal interactome.

What approaches can resolve discrepancies in MRPL45 antibody detection between different experimental techniques?

Researchers may encounter discrepancies when using the same MRPL45 antibody across different experimental platforms. These inconsistencies can arise from technique-specific variables affecting epitope accessibility, protein conformation, or detection sensitivity.

When facing discrepancies between Western blot and immunohistochemistry results, consider that WB detects denatured proteins while IHC detects proteins in their native tissue context. If an MRPL45 antibody works in WB but not IHC, the epitope may be masked in the tissue environment. Try alternative antigen retrieval methods, such as extending retrieval time or testing both acidic (citrate buffer, pH 6.0) and basic (TE buffer, pH 9.0) retrieval solutions as recommended for MRPL45 antibodies .

For discrepancies between immunofluorescence and Western blot, consider fixation conditions. Paraformaldehyde, commonly used for IF, can modify protein epitopes differently than SDS denaturation used in WB. If needed, test alternative fixation methods like methanol or acetone. Additionally, subcellular localization can affect detection - MRPL45's mitochondrial localization may result in concentrated signal in IF but appear less prominent in whole-cell lysate WB.

Quantitative discrepancies may reflect technical differences in detection limits. Western blot has a broader dynamic range but lower spatial resolution compared to microscopy-based techniques. Consider using multiple antibodies targeting different epitopes of MRPL45 to validate your observations across techniques.

Document the specific conditions yielding positive results for each application:

How can MRPL45 antibodies be employed in multiplex immunoassays for mitochondrial research?

Multiplex immunoassays enable simultaneous detection of MRPL45 alongside other mitochondrial proteins, providing a comprehensive view of mitochondrial dynamics and function. Several approaches can be employed, each with specific technical considerations.

For fluorescence-based multiplex immunohistochemistry or immunocytochemistry, select primary antibodies from different host species to avoid cross-reactivity between secondary antibodies. When using multiple rabbit antibodies including MRPL45 antibodies, consider sequential staining with tyramide signal amplification (TSA), which allows antibody stripping between rounds while preserving the amplified signal. The conjugated NBP2-97306JF549 antibody is particularly useful in multiplex settings as it eliminates the need for a secondary antibody step for MRPL45 detection .

For flow cytometry applications, combine MRPL45 staining with mitochondrial membrane potential dyes (e.g., TMRE, JC-1) or mitochondrial mass indicators (e.g., MitoTracker Green). This approach can correlate MRPL45 expression with functional mitochondrial parameters at the single-cell level.

In Western blot multiplexing, consider size separation of target proteins. MRPL45's molecular weight of ~35 kDa allows co-detection with larger or smaller mitochondrial proteins on the same membrane using differently colored detection systems. Alternatively, sequential probing with stripping between antibodies can be employed, though protein loss during stripping should be considered.

For quantitative multiplex assays, Luminex or Meso Scale Discovery platforms can be adapted for MRPL45 detection alongside other targets, though this requires antibody pairs with confirmed specificity and non-overlapping epitopes.

What role does MRPL45 play in mitochondrial dysfunction, and how can antibodies help investigate this relationship?

MRPL45, as a component of the mitochondrial ribosome large subunit, plays a critical role in mitochondrial protein synthesis. Dysfunction of MRPL45 can impair the translation of mitochondrially-encoded proteins, particularly components of the electron transport chain, leading to compromised oxidative phosphorylation and increased reactive oxygen species production.

Antibody-based approaches can elucidate MRPL45's role in several ways. Immunohistochemistry with validated MRPL45 antibodies (15682-1-AP, 66531-1-Ig) can assess MRPL45 expression patterns in disease tissues compared to healthy controls . This is particularly relevant for conditions like neurodegenerative disorders, cancer, and mitochondrial diseases where altered mitochondrial function is implicated.

For functional studies, combine MRPL45 antibody detection with assays measuring mitochondrial respiration (such as Seahorse XF analysis) or membrane potential. This correlative approach can reveal relationships between MRPL45 expression levels and functional mitochondrial parameters.

To investigate MRPL45's role in mitochondrial ribosome assembly, use immunoprecipitation with 15682-1-AP followed by mass spectrometry to identify associated proteins under normal and stress conditions . Alternatively, proximity labeling methods can map the MRPL45 interaction network within the mitochondrial ribosome.

For dynamic studies, pair MRPL45 antibodies with time-course experiments examining mitochondrial stress responses. This can reveal how MRPL45 levels or post-translational modifications change during adaptation to metabolic challenges, providing insight into mitochondrial quality control mechanisms.

How can MRPL45 antibodies be utilized in cancer research to understand mitochondrial alterations?

Mitochondrial alterations represent a hallmark of cancer, and MRPL45 antibodies can provide valuable insights into these changes. Several research approaches can leverage MRPL45 antibodies for cancer investigations.

Tissue microarray (TMA) analysis using immunohistochemistry with MRPL45 antibodies can evaluate expression patterns across multiple cancer types and stages. Both 15682-1-AP and 66531-1-Ig have been validated for IHC applications in cancer tissues, with positive detection reported in human ovary tumor tissue and breast cancer tissue, respectively .

For mechanistic studies, examine correlations between MRPL45 expression and cancer cell bioenergetics. Combine Western blot quantification of MRPL45 using 66531-1-Ig (recommended at 1:2500-1:10000 dilution) with functional assays measuring glycolysis versus oxidative phosphorylation to assess whether MRPL45 alterations contribute to the Warburg effect .

In cell line models, use immunofluorescence with 15682-1-AP (1:200-1:800 dilution) to assess subcellular distribution of MRPL45 in normal versus transformed cells . Co-staining with markers of mitochondrial dynamics (e.g., DRP1, MFN2) can reveal whether MRPL45 alterations correlate with changes in mitochondrial morphology characteristically observed in cancer.

For translational research, correlate MRPL45 expression with patient outcomes and treatment responses. This approach may identify potential prognostic or predictive biomarker applications, particularly in cancers where mitochondrial function influences therapeutic efficacy, such as those treated with mitochondria-targeting agents.

How can MRPL45 antibodies be integrated with advanced imaging techniques for mitochondrial research?

Integration of MRPL45 antibodies with cutting-edge imaging technologies offers unprecedented insights into mitochondrial biology at multiple scales. Several promising approaches are emerging in this area.

Super-resolution microscopy techniques (STED, STORM, PALM) can overcome the diffraction limit of conventional microscopy, enabling visualization of MRPL45 distribution within mitochondrial subcompartments. The directly conjugated NBP2-97306JF549 antibody is particularly suited for super-resolution applications due to the photostability of Janelia Fluor dyes . For these applications, sample preparation requires careful optimization of fixation and permeabilization to preserve nanoscale structures while ensuring antibody accessibility.

Correlative light and electron microscopy (CLEM) combines immunofluorescence detection of MRPL45 with ultrastructural analysis by electron microscopy. This approach can precisely localize MRPL45 within the mitochondrial fine structure, particularly at sites of mitochondrial translation. For CLEM applications, specialized fixation protocols compatible with both immunolabeling and electron microscopy are required.

Live-cell imaging of MRPL45 can be achieved through knock-in of fluorescent tags using CRISPR-Cas9 genome editing, complemented by validation with fixed-cell antibody staining using 15682-1-AP or CAB13197 . This approach enables tracking of MRPL45 dynamics during mitochondrial processes like translation, quality control, or stress responses.

Expansion microscopy physically enlarges specimens after immunolabeling, providing enhanced resolution with standard confocal microscopy. When applying this technique with MRPL45 antibodies, ensure the antibody concentration is optimized for the expanded specimen volume.

What are the considerations for using MRPL45 antibodies in single-cell analysis techniques?

Single-cell analysis of MRPL45 can reveal heterogeneity in mitochondrial properties within seemingly homogeneous populations. Several methodological considerations are important when applying MRPL45 antibodies to single-cell techniques.

Single-cell proteomics combining flow cytometry with mass spectrometry (CyTOF) can incorporate metal-conjugated MRPL45 antibodies to quantify expression alongside dozens of other protein markers. This requires careful antibody panel design to avoid signal spillover and validation of the metal-conjugated antibody against unconjugated versions.

For spatial single-cell analysis, techniques like imaging mass cytometry or multiplexed ion beam imaging can utilize metal-labeled MRPL45 antibodies to map expression within tissue architecture at subcellular resolution. These approaches preserve spatial context while enabling quantitative single-cell analysis.

Single-cell immunofluorescence can be combined with laser capture microdissection to isolate cells with specific MRPL45 expression patterns for downstream molecular analysis. This approach requires optimization of immunostaining protocols to preserve RNA and DNA quality for subsequent analysis.